REMEDIUM

Introduction. In the Russian pharmaceutical market, there is the following situation: herbal medicinal products (HMP) and dietary supplements based on plant raw materials (DS) have similar compositions, dosage forms and scope of application. They’re often considered analogues by consumers and specialists, which indicates the existence of common market for these products.Research aim is to investigate the state and development trends of the Russian HMP and DS market, assessing positions of foreign and domestic companies and general prospects for this market as well.Methodology. The study was conducted using IQVIA retail audit database, official sources of information on HMP and DS registration. In the market analysis the products were classified depending on the scope of application, composition and preparation methods, and dosage forms as well.Results. In 2020 pharmacy of HMP and DS sales amounted to 435.4 million units valued at 51.3 billion rubles in wholesale prices. Beginning with 2016, the average annual growth rate corresponded to 4.2%, in value terms. However, in volume terms, the sales were reduced in the average by 3.4% per year (due to cheap domestic medicines). The main part of the entire market comprises HMP (80% in units and 74% in value terms in 2020). The products, affecting respiratory system, genitourinary sphere, and digestion, provide more than three-quarters of all sales in value terms. More than half of the market is occupied by total extractive drugs. Solid dosage forms (tablets and capsules) account for half of the sales, plant raw materials and fees constitute more than one third. In 2020, Russian companies provided 28% of the sales of HMP and 67% of DS in value terms. In the context of the main segments, the market structure in 2016-2020 remained fairly stable.Conclusion. In the future, the market dynamics in value terms will be determined considering by household income and the epidemiological situation. In units, HMP sales will continue to decline through the unprofitable positions of the traditional domestic drug assortment. The increasing strictness of legislation requirements for the market of dietary supplements may contribute to investment in the development of HMP that are competitive to foreign products in terms of quality and consumer characteristics.

Традиционно 22 июля мир отметил День мозга, посвященный повышению осведомленности населения планеты о важности здоровья мозга и о наиболее распространенных заболеваниях головного мозга и нервной системы, включая патологическую тревогу. О проблемах пациентов, страдающих тревожными состояниями, и современных подходах к их лечению мы решили поговорить с Ольгой ВОРОБЬЕВОЙ, профессором кафедры нервных болезней ИПО Первого МГМУ им. И.М. Сеченова, специалистом высшей квалификационной категории, д.м.н.

Гормональные противозачаточные таблетки, разработанные более 60 лет назад, совершили настоящую революцию в контрацепции. С тех пор медицина шагнула далеко вперед, и сегодня женщины имеют возможность применять безопасные и удобные контрацептивы при планировании беременности. Серьезные шаги были сделаны и в развитии менопаузальной гормональной терапии, играющей значительную роль в сохранении здоровья женщин зрелого возраста.О современных подходах к сохранению женского здоровья, в т. ч. в условиях пандемии COVID-19, мы решили поговорить со Светланой ЮРЕНЕВОЙ, д.м.н., ведущим научным сотрудником отделения гинекологической эндокринологии, профессором кафедры акушерства и гинекологии ФГБУ «НМИЦ акушерства, гинекологии и перинатологии имени В.И. Кулакова».

The Russian market of biologically active additives, which include pancreatine and pancreatic enzymes — amylase, protease, lipase, has been analyzed. It was established that the study group is represented by a wide range (approximately 150 names), which is represented mainly by foreign manufacturers (approximately 80%). The monotonous tendency to increase sales by volume in all regions of the Russian Federation over the past 5 years has been analyzed. It should be noted that, today consumer preferences biologically active additives of domestic production despite the significant share of imported dietary supplements in the supply structure. High demand is primarily due to the accessibility and increased trust and loyalty of modern consumers to national producers of biologically active additives .

Diabetes mellitus (DM) has become a global and national menace. The number of patients with diabetes in the Russian Federation tallied roughly 5.1 million, according to the incidence of outpatient visits in 2020 [1]. “Do-it-yourself” regular measurements of blood glucose levels (self-monitoring) are one of the most important components in achieving the therapy goals for patients with diabetes and preventing severe vascular complications. Now that the technologies have caught on, new “smart” glucometers appeared, which enable remote control and significantly expand opportunities of DM monitoring due to free mobile application integration.

The authors studied the availability of gene therapy drugs in the Russian Federation on the basis of information on the permission of the medical use of drugs of this group in the world. Literature data and information about medicines approved by the FDA, EMA and the Ministry of Health of Russia were used. In general, the FDA registered only 13 drugs (46%) of the total approved for medical use in the world, 2 of them have already been withdrawn from the market, and 2 additional clinical trials are underway. In Europe, the EMA has approved 16 drugs for medical use (57%), with 4 of them already withdrawn. Most of the drugs were first approved by the FDA, and then, on average, a year later, were approved in the European market. A total of 4 drugs were approved in the European market and were not approved by the FDA at the time the data was requested. And only 1 drug, approved in the USA, is not registered in Europe. In the Russian Federation, two medicines are allowed, Neovasculgen (2011) and Spinraza (2019). This is only 7% of the total number of gene therapy drugs on the world market. Most of the drugs are intended for the treatment of orphan diseases and are cost expensive. This can explain the unevenness of their distribution across regions.

Financial status is the most important characteristic of the economic activity of the industry enterprises, which determines its economic attractiveness. Let us consider a set of indicators reflecting the availability, placement and use of financial resources of enterprises in the industry.Financial status of pharmaceutical companies is analysed using the data form State Statistical Reporting Form No. P-3 – Information on Company Financial Status.

До 2014 г. на российском фармацевтическом рынке «СИА» Интернейшнл» была второй по величине и успешности компанией. Ее мозгом, нервом, лицом и душой был владелец – Игорь Феликсович Рудинский. О нем вспоминают как о фантастическом человеке, говорят либо очень серьезно: «Игорь Феликсович был one man show1, гений. Он все держал в уме и сам всем управлял», либо иронически: «Вообще, с Игорем Рудинским было много интересных историй, талантливый был человек» [1]. Он сам создал «СИА» с нуля, сам владел, сам определял ее стратегию и тактику, сам участвовал в процессах, силой обаяния и опыта влиял на жизнь многих вовлеченных в фармбизнес людей. Судя по воспоминаниям, «СИА» Интернейшнл» была воплощением коммуникативных талантов Рудинского, его умения договариваться, его страсти к новому и неизведанному.

По итогам июня 2021 г. в сегменте фармацевтической рекламы в категории «Лекарственные препараты и биологически активные добавки» (ЛП и БАД) на топ-20 рекламодателей суммарно по всем типам СМИ пришлось более 60 тыс. выходов рекламы, а на топ-20 марок ЛП и БАД – более 31 тыс. выходов.